Temozolamide

Detalhes bibliográficos
Autor(a) principal: Najman, Henry
Data de Publicação: 2002
Outros Autores: Gadelha, Maria Inez Pordeus
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/2220
Resumo: Temozolamide (TMZ) is a new class of alkylating agents deriving from imidazotetrazine. TMZ is a substance of low molecular weight, and 100% of it is absorbed via the oral route; and it is eliminated by the body about 8 hours after intake. Due to the swift elimination ratio and to its action, TMZ presents decreased risk of being toxic to the marrow bone. On the other hand, being a lipophylic substance, TMZ crosses the blood-brain barrier and may reach brain tumors. This drug is active againt some solid tumors, and it has been studied for the treatment of highgrade gliomas, including anaplastic astrocytoma (AA), multiform glioblastoma (GBM), low-grade gliomas, and metastatic malignant melanoma (MM). This bibliography review made evident the lack of scientific grounds to allow TMZ to be a standard treatment for brain tumors or metastatic malignant melanoma.
id INCA-1_4903e31faea5ffa39b4af7207cb6a6fb
oai_identifier_str oai:rbc.inca.gov.br:article/2220
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling TemozolamideTemozolamidaTemozolamidaAstrocitomaGliomaOligodendrogliomaMelanomaOligoastrocitomaNeoplasias CerebraisQuimioterapiaTemozolamideAstrocytomaGliomaOligodendrogliomaMelanomaOligoastrocytomaBrain NeoplasmsChemotherapyTemozolamide (TMZ) is a new class of alkylating agents deriving from imidazotetrazine. TMZ is a substance of low molecular weight, and 100% of it is absorbed via the oral route; and it is eliminated by the body about 8 hours after intake. Due to the swift elimination ratio and to its action, TMZ presents decreased risk of being toxic to the marrow bone. On the other hand, being a lipophylic substance, TMZ crosses the blood-brain barrier and may reach brain tumors. This drug is active againt some solid tumors, and it has been studied for the treatment of highgrade gliomas, including anaplastic astrocytoma (AA), multiform glioblastoma (GBM), low-grade gliomas, and metastatic malignant melanoma (MM). This bibliography review made evident the lack of scientific grounds to allow TMZ to be a standard treatment for brain tumors or metastatic malignant melanoma.A temozolamida (TMZ) pertence a uma nova classe de agentes alquilantes, como um derivado da imidazotetrazina. A TMZ é uma substância de baixo peso molecular, sendo 100% absorvida por via oral, e praticamente toda ela deverá ter sido eliminada após 8 horas da ingestão. Devido a esta rápida eliminação e ao seu mecanismo de ação, a TMZ tem risco reduzido de ser tóxica para a medula óssea. Por outro lado, em sendo uma substância lipofílica, a TMZ atravessa a barreira hemo-encefálica, o que a faz alcançar tumores cerebrais. Este medicamento apresenta atividade contra alguns tumores sólidos e tem sido investigada para tratamento de gliomas de alto grau, incluindo o Astrocitoma anaplásico (AA), o Glioblastoma multiforme (GBM), gliomas de baixo grau e o Melanoma maligno metastático (MM). Com a presente revisão bibliográfica, evidenciou-se ausência de bases técnicas e científicas que permitam considerar o TMZ um tratamento padrão dos tumores cerebrais ou do melanoma maligno metastático.INCA2002-09-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisão de literaturaapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/222010.32635/2176-9745.RBC.2002v48n3.2220Revista Brasileira de Cancerologia; Vol. 48 No. 3 (2002): July/Aug./Sept.; 439-445Revista Brasileira de Cancerologia; Vol. 48 Núm. 3 (2002): jul./ago./sept.; 439-445Revista Brasileira de Cancerologia; v. 48 n. 3 (2002): jul./ago./set.; 439-4452176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/2220/1381Najman, HenryGadelha, Maria Inez Pordeusinfo:eu-repo/semantics/openAccess2021-11-29T20:37:35Zoai:rbc.inca.gov.br:article/2220Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:37:35Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Temozolamide
Temozolamida
title Temozolamide
spellingShingle Temozolamide
Najman, Henry
Temozolamida
Astrocitoma
Glioma
Oligodendroglioma
Melanoma
Oligoastrocitoma
Neoplasias Cerebrais
Quimioterapia
Temozolamide
Astrocytoma
Glioma
Oligodendroglioma
Melanoma
Oligoastrocytoma
Brain Neoplasms
Chemotherapy
title_short Temozolamide
title_full Temozolamide
title_fullStr Temozolamide
title_full_unstemmed Temozolamide
title_sort Temozolamide
author Najman, Henry
author_facet Najman, Henry
Gadelha, Maria Inez Pordeus
author_role author
author2 Gadelha, Maria Inez Pordeus
author2_role author
dc.contributor.author.fl_str_mv Najman, Henry
Gadelha, Maria Inez Pordeus
dc.subject.por.fl_str_mv Temozolamida
Astrocitoma
Glioma
Oligodendroglioma
Melanoma
Oligoastrocitoma
Neoplasias Cerebrais
Quimioterapia
Temozolamide
Astrocytoma
Glioma
Oligodendroglioma
Melanoma
Oligoastrocytoma
Brain Neoplasms
Chemotherapy
topic Temozolamida
Astrocitoma
Glioma
Oligodendroglioma
Melanoma
Oligoastrocitoma
Neoplasias Cerebrais
Quimioterapia
Temozolamide
Astrocytoma
Glioma
Oligodendroglioma
Melanoma
Oligoastrocytoma
Brain Neoplasms
Chemotherapy
description Temozolamide (TMZ) is a new class of alkylating agents deriving from imidazotetrazine. TMZ is a substance of low molecular weight, and 100% of it is absorbed via the oral route; and it is eliminated by the body about 8 hours after intake. Due to the swift elimination ratio and to its action, TMZ presents decreased risk of being toxic to the marrow bone. On the other hand, being a lipophylic substance, TMZ crosses the blood-brain barrier and may reach brain tumors. This drug is active againt some solid tumors, and it has been studied for the treatment of highgrade gliomas, including anaplastic astrocytoma (AA), multiform glioblastoma (GBM), low-grade gliomas, and metastatic malignant melanoma (MM). This bibliography review made evident the lack of scientific grounds to allow TMZ to be a standard treatment for brain tumors or metastatic malignant melanoma.
publishDate 2002
dc.date.none.fl_str_mv 2002-09-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Revisão de literatura
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/2220
10.32635/2176-9745.RBC.2002v48n3.2220
url https://rbc.inca.gov.br/index.php/revista/article/view/2220
identifier_str_mv 10.32635/2176-9745.RBC.2002v48n3.2220
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/2220/1381
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 48 No. 3 (2002): July/Aug./Sept.; 439-445
Revista Brasileira de Cancerologia; Vol. 48 Núm. 3 (2002): jul./ago./sept.; 439-445
Revista Brasileira de Cancerologia; v. 48 n. 3 (2002): jul./ago./set.; 439-445
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042250024222720

Registros relacionados